Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Recruiting · NCT06846463 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm | Recruiting | Phase 2 | 2026-01-23 | NCT06846463 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Virginia Commonwealth University | 122 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Virginia Commonwealth University | Richmond | United States | 156 |